Back To: Home : Featured Technology : Liquid Biopsy

CLICK HERE FOR WHAT'S NEW IN:
 

MDxHealth recognized for prostate cancer Dx efforts
March 2016
SHARING OPTIONS:

IRVINE, Calif. & HERSTAL, Belgium—MDxHealth SA ended January with the news that it had  received the 2016 Frost & Sullivan Global Technology Innovation Award for its commitment to technological innovation in the effort to reduce unnecessary prostate biopsies. The award is presented to “the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impacts both the functionality and the customer value of the new products and applications. The award lauds the high R&D spend toward innovation, its relevance to the industry and the positive impact on brand perception,” according to Frost & Sullivan.
 
MDxHealth’s flagship product, the ConfirmMDx for Prostate Cancer test, and its recently launched “liquid biopsy” test,  SelectMDx for Prostate Cancer, are key to this commendation, with Frost & Sullivan Senior Industry Analyst Divyaa Ravishankar noting “Frost & Sullivan believes that these two offerings can significantly reduce the number of men undergoing unnecessary invasive biopsy procedures, and importantly helps avoid the associated pain, risk of complications, and cost.”

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.